Ischemia-reperfusion treatment: opportunities point to modulation of the inflammatory response.
Ischemia-reperfusion injury is the leading cause of acute renal failure and determinant of renal-transplant outcome. Although many experimental studies show decreased injury and preserved renal function after dampening of the inflammatory response, surprisingly little progress has been made in the development of novel therapies.
Department of Radiation Oncology (MAASTRO Lab), Research Institute Growth and Development (GROW), Maastricht University, Maastricht, The Netherlands. kasper.rouschop@maastro.unimaas.nl
K M A
KM
Rouschop
J C
JC
Leemans
D000818:Animals; D018925:Chemokines / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D006084:Graft Rejection / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D007668:Kidney / Q000098:blood supply* / Q000378:metabolism; D016030:Kidney Transplantation; D051379:Mice; D009393:Nephritis / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D051437:Renal Insufficiency / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D015427:Reperfusion Injury / Q000150:complications / Q000378:metabolism / Q000628:therapy*
D018925:Chemokines; D016207:Cytokines